White Paper

New Product Alert - Ribociclib

is a cancer medication that works by inhibiting the activity of specific enzymes called cyclin-dependent kinases (CDKs) 4 and 6. These enzymes play a critical role in the regulation of cell division, and their overactivity is commonly associated with the development of certain types of cancer, particularly breast cancer

By blocking the activity of CDK4/6, Ribociclib slows down the uncontrolled cell division that drives the growth of cancer cells. This helps to reduce the size of tumors and slows down the progression of the disease

Our Offerings*:

• We provide Novel Form X and Innovator Form A, with non-GMP API available at kg scale and a short lead time of 90 days.
• As an early mover in Ribociclib API development, we plan to submit the USDMF for Form X by June 2025 and for Form A by September 2025.
• Our commitment to regulatory compliance and quality ensures our API is genotoxic and nitrosamine-free, adhering to ICH M7 guidelines.
• We offer immediate samples with CoA and impurity profiles, allowing you to evaluate our API's quality and suitability.

To learn more about our API offerings, please read the Product alert on Ribociclib by filling out the contact form below.